This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
by Ekta Bagri
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
by Zacks Equity Research
Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
by Zacks Equity Research
Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
by Zacks Equity Research
SAGE and AKRO are up this week on regulatory and pipeline updates.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
by Zacks Equity Research
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
by Zacks Equity Research
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
by Zacks Equity Research
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
by Zacks Equity Research
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Denali Gains 26.6% in a Year: How Should You Play the Stock?
by Zacks Equity Research
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
by Zacks Equity Research
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
by Zacks Equity Research
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
by Zacks Equity Research
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
by Zacks Equity Research
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
by Kinjel Shah
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
Denali Starts Dosing in Phase II Parkinson's Disease Study
by Zacks Equity Research
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.